Head And Neck Cancer - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Head And Neck Cancer - Pipeline Review, H2 2018’, provides an overview of the Head And Neck Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer

- The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects

- The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Abion Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Admedus Ltd

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Affimed GmbH

Alkermes ...

4SC AG

AbbVie Inc

Abion Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Admedus Ltd

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Affimed GmbH

Alkermes Plc

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

AMI Onco Theranostics LLC

Apexigen Inc

Arcus Biosciences Inc

Argenx SE

ArQule Inc

Array BioPharma Inc

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Benitec Biopharma Ltd

Bexion Pharmaceuticals LLC

Biohaven Pharmaceutical Holding Company Ltd

BioLineRx Ltd

Biomics Biotechnologies Co Ltd

Bionovis SA

BioNTech AG

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Cantargia AB

CBT Pharmaceuticals Inc

CEL-SCI Corp

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celprogen Inc

Checkpoint Therapeutics Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

Cue Biopharma Inc

Curevac AG

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Denceptor Therapeutics Ltd

DNJ Pharma Inc

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Enzene Biosciences Ltd

Etubics Corp

Eureka Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FLX Bio Inc

Forbius

Forty Seven Inc

Fujifilm Holdings Corporation

G&E Corp

Galectin Therapeutics Inc

Genelux Corp

Genentech Inc

GeneSegues Inc

Genmab A/S

Genocea Biosciences Inc

GeoVax Labs Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gliknik Inc

Glycotope GmbH

GT Biopharma Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Hercules Pharmaceuticals BV

Hookipa Biotech AG

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

Immatics Biotechnologies GmbH

Immunicum AB

Immunocore Ltd

Immunomedics Inc

Immunomic Therapeutics Inc

Immunovative Therapies Ltd

Immutep Ltd

IMV Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Innate Pharma SA

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Iovance Biotherapeutics Inc

Ipsen SA

IRX Therapeutics Inc

ISA Pharmaceuticals BV

ISU ABXIS Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

Juno Therapeutics Inc

Kiromic Inc

Kite Pharma Inc

Kura Oncology Inc

Laboratoires Pierre Fabre SA

LATITUDE Pharmaceuticals Inc

LIfT BioSciences Ltd

Loxo Oncology Inc

Lycera Corp

Lytix Biopharma AS

Mabion SA

MacroGenics Inc

Marsala Biotech Inc

Mateon Therapeutics Inc

MaxiVAX SA

MediciNova Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Moleculin Biotech LLC

NanoCarrier Co Ltd

NantKwest Inc

Natco Pharma Ltd

Nektar Therapeutics

NeoImmuneTech Inc

Neonc Technologies Inc

Neumedicines Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxopharm Ltd

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford Vacmedix UK Ltd

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

Philogen SpA

Phosplatin Therapeutics LLC

Plexxikon Inc

PNP Therapeutics Inc

Profectus BioSciences Inc

PsiOxus Therapeutics Ltd

Qilu Pharmaceutical Co Ltd

R Pharm

Rakuten Aspyrian Inc

Regeneron Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

RXi Pharmaceuticals Corp

Sanofi

Sareum Holdings Plc

Selecta Biosciences Inc

Sensei Biotherapeutics Inc

Shanghai Henlius Biotech Co Ltd

Shionogi & Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Sinil Pharmaceutical Co Ltd

Sino Biopharmaceutical Ltd

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sound Pharmaceuticals Inc

Spherium Biomed SL

Sumitomo Dainippon Pharma Co Ltd

SuviCa Inc

Symphogen A/S

Synermore Biologics Co Ltd

Systimmune Inc

Takis Srl

Telix Pharmaceuticals Ltd

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Theravectys SA

Tocagen Inc

Tolero Pharmaceuticals Inc

Tosk Inc

Transgene SA

Trovagene Inc

UbiVac LLC

Vaccibody AS

Vaccinex Inc

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

Vectorite Biomedical Inc

Venus Remedies Ltd

Viracta Therapeutics Inc

Viralytics Ltd

Virion Therapeutics LLC

Vyriad Inc

Xencor Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Head And Neck Cancer – Overview 11

Head And Neck Cancer – Therapeutics Development 12

Head And Neck ...

Table of Contents

Table of Contents 2

Introduction 10

Head And Neck Cancer – Overview 11

Head And Neck Cancer – Therapeutics Development 12

Head And Neck Cancer – Therapeutics Assessment 63

Head And Neck Cancer – Companies Involved in Therapeutics Development 90

Head And Neck Cancer – Drug Profiles 198

Head And Neck Cancer – Dormant Projects 1925

Head And Neck Cancer – Discontinued Products 1939

Head And Neck Cancer – Product Development Milestones 1942

Appendix 1956

List of Tables

List of Tables

Number of Products under Development for Head And Neck Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Tables

Number of Products under Development for Head And Neck Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Head And Neck Cancer – Pipeline by 4SC AG, H2 2018

Head And Neck Cancer – Pipeline by AbbVie Inc, H2 2018

Head And Neck Cancer – Pipeline by Abion Inc, H2 2018

Head And Neck Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2018

Head And Neck Cancer – Pipeline by ADC Therapeutics SA, H2 2018

Head And Neck Cancer – Pipeline by Admedus Ltd, H2 2018

Head And Neck Cancer – Pipeline by Aduro BioTech Inc, H2 2018

Head And Neck Cancer – Pipeline by Advaxis Inc, H2 2018

Head And Neck Cancer – Pipeline by Advenchen Laboratories LLC, H2 2018

Head And Neck Cancer – Pipeline by Affimed GmbH, H2 2018

Head And Neck Cancer – Pipeline by Alkermes Plc, H2 2018

Head And Neck Cancer – Pipeline by Altor BioScience Corp, H2 2018

Head And Neck Cancer – Pipeline by Ambrx Inc, H2 2018

Head And Neck Cancer – Pipeline by amcure GmbH, H2 2018

Head And Neck Cancer – Pipeline by Amgen Inc, H2 2018

Head And Neck Cancer – Pipeline by AMI Onco Theranostics LLC, H2 2018

Head And Neck Cancer – Pipeline by Apexigen Inc, H2 2018

Head And Neck Cancer – Pipeline by Arcus Biosciences Inc, H2 2018

Head And Neck Cancer – Pipeline by Argenx SE, H2 2018

Head And Neck Cancer – Pipeline by ArQule Inc, H2 2018

Head And Neck Cancer – Pipeline by Array BioPharma Inc, H2 2018

Head And Neck Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018

Head And Neck Cancer – Pipeline by Astellas Pharma Inc, H2 2018

Head And Neck Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2018

Head And Neck Cancer – Pipeline by AstraZeneca Plc, H2 2018

Head And Neck Cancer – Pipeline by Atara Biotherapeutics Inc, H2 2018

Head And Neck Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Head And Neck Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Head And Neck Cancer – Pipeline by Bayer AG, H2 2018

Head And Neck Cancer – Pipeline by BeiGene Ltd, H2 2018

Head And Neck Cancer – Pipeline by Benitec Biopharma Ltd, H2 2018

Head And Neck Cancer – Pipeline by Bexion Pharmaceuticals LLC, H2 2018

Head And Neck Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Head And Neck Cancer – Pipeline by BioLineRx Ltd, H2 2018

Head And Neck Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H2 2018

Head And Neck Cancer – Pipeline by Bionovis SA, H2 2018

Head And Neck Cancer – Pipeline by BioNTech AG, H2 2018

Head And Neck Cancer – Pipeline by Biothera Pharmaceutical Inc, H2 2018

Head And Neck Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Head And Neck Cancer – Pipeline by Boston Biomedical Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Head And Neck Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Figures

Number of Products under Development for Head And Neck Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports